Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 8, 2026, 9:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 129 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Anti-TNF therapy Clear all
Terminated Phase 3 Interventional Results available

A Study of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Who Don't Have a Response to Anti-TNF-α Therapy (SCRIPT)

NCT00476996
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Leflunomide, Methotrexate, Ocrelizumab, Placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
836 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2018
U.S. locations
144
States / cities
Anniston, Alabama • Birmingham, Alabama • Huntsville, Alabama + 116 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2019 · Synced Sep 8, 2026, 9:14 PM EDT
Completed Phase 3 Interventional Results available

A Study of CNTO 136 (Sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Patients With Active Rheumatoid Arthritis Despite Anti-TNF-Alpha Therapy (SIRROUND-T)

NCT01606761
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
Placebo, Sirukumab
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
878 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
81
States / cities
Birmingham, Alabama • Glendale, Arizona • Mesa, Arizona + 78 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2018 · Synced Sep 8, 2026, 9:14 PM EDT
Completed No phase listed Observational Results available

Drug Concentration, Immunogenicity, and Efficacy Study in Patients With Rheumatoid Arthritis Currently Treated With Etanercept, Adalimumab, or Infliximab

NCT01981473
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
no intervention
Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
605 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
34
States / cities
Glendale, Arizona • Mesa, Arizona • Phoenix, Arizona + 29 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2016 · Synced Sep 8, 2026, 9:14 PM EDT
Completed Phase 2 Interventional Results available

A Study of Bermekimab in Patients With Hidradenitis Suppurativa

NCT03512275
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Bermekimab Monoclonal Antibody 400 mg
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 13, 2022 · Synced Sep 8, 2026, 9:14 PM EDT
Not listed Phase 2 Interventional

Dose-Finding Study of REN-1654 in Patients With Post-Herpetic Neuralgia

NCT00099528
View directory record Official record
Conditions
Neuralgia, Shingles, Peripheral Nervous System Disease
Interventions
REN-1654
Drug
Lead sponsor
Renovis
Industry
Eligibility
55 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
16
States / cities
Huntsville, Alabama • Peoria, Arizona • Phoenix, Arizona + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2010 · Synced Sep 8, 2026, 9:14 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Adalimumab in Patients With Active Rheumatoid Arthritis Treated Concomitantly With Methotrexate.

NCT00195702
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Adalimumab, Placebo
Biological · Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
619 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2010
U.S. locations
76
States / cities
Huntsville, Alabama • Mobile, Alabama • Phoenix, Arizona + 64 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2011 · Synced Sep 8, 2026, 9:14 PM EDT
Completed Phase 4 Interventional Results available

Anti-TNF Agents for the Treatment of Rheumatoid Arthritis

NCT00837434
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Etanercept, Adalimumab
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 75 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
7
States / cities
Birmingham, Alabama • San Francisco, California • New Haven, Connecticut + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2021 · Synced Sep 8, 2026, 9:14 PM EDT
Not yet recruiting Phase 4 Interventional

Adalimumab Dose Adjustment for Pediatric Uveitis Treatment Trial

NCT07699107
View directory record Official record
Conditions
Juvenile Idiopathic Arthritis Associated Uveitis, Uveitis, Anterior
Interventions
Adalimumab/Biosimilar
Biological
Lead sponsor
Nisha Acharya
Other
Eligibility
2 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
9
States / cities
Los Angeles, California • Sacramento, California • San Francisco, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Sep 8, 2026, 9:14 PM EDT
Terminated Phase 2 Interventional Results available

Andecaliximab as Add-On Therapy to a Tumor Necrosis Factor Inhibitor and Methotrexate Regimen in Adults With Moderately to Severely Active Rheumatoid Arthritis

NCT02862574
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Andecaliximab, Placebo, Methotrexate, TNF Inhibitor
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
8
States / cities
Palo Alto, California • DeBary, Florida • Las Vegas, Nevada + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2018 · Synced Sep 8, 2026, 9:14 PM EDT
Recruiting Phase 4 Interventional

Clinical, Imaging, and Endoscopic Outcomes of Children Newly Diagnosed With Crohn's Disease

NCT05781152
View directory record Official record
Conditions
Crohn Disease
Interventions
Anti-TNF therapy
Drug
Lead sponsor
Connecticut Children's Medical Center
Other
Eligibility
6 Years to 17 Years
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
22
States / cities
Phoenix, Arizona • Los Angeles, California • San Diego, California + 19 more
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Sep 8, 2026, 9:14 PM EDT
Completed Phase 4 Interventional Results available

Anti-inflammatory Therapy to Improve Outcomes After TPIAT

NCT02713997
View directory record Official record
Conditions
Pancreatitis, Chronic; Diabetes; Transplant
Interventions
etanercept, Alpha 1-Antitrypsin
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 65 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Sep 8, 2026, 9:14 PM EDT
Completed No phase listed Observational Results available

Comparative Effectiveness of Biologics or Small Molecule Therapies in Inflammatory Bowel Disease (IBD)

NCT04852666
View directory record Official record
Conditions
Crohn's Disease, Ulcerative Colitis
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
465 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
2
States / cities
New York, New York • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 13, 2024 · Synced Sep 8, 2026, 9:14 PM EDT
Completed Phase 4 Interventional Results available

A Study of Baricitinib in Participants With Rheumatoid Arthritis

NCT04086745
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Baricitinib, TNF Inhibitor
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,050 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
119
States / cities
Chandler, Arizona • Mesa, Arizona • Paradise Valley, Arizona + 104 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Sep 8, 2026, 9:14 PM EDT
Recruiting Phase 1 Interventional

Imaging of Lymphatic Vessels in People With Rheumatoid Arthritis (RA)

NCT05197530
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Indocyanine green, MultiSpectral Imaging System
Drug · Device
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Sep 8, 2026, 9:14 PM EDT
Completed Phase 4 Interventional

COVID-19 VaccinE Response in Rheumatology Patients

NCT05080218
View directory record Official record
Conditions
Rheumatoid Arthritis, Psoriatic Arthritis, Spondylarthritis
Interventions
Upadacitinib, Abatacept, Secukinumab, Tofacitinib, TNF Inhibitor, Canakinumab Injection, Baricitinib, Ixekizumab
Drug
Lead sponsor
Jeffrey Curtis
Other
Eligibility
18 Years to 85 Years
Enrollment
841 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
8
States / cities
Birmingham, Alabama • Hoover, Alabama • Phoenix, Arizona + 4 more
Source: ClinicalTrials.gov public record
Updated May 1, 2025 · Synced Sep 8, 2026, 9:14 PM EDT
Active, not recruiting Phase 2 Interventional

Treatment of Type 1 Diabetes With Anti-OX40L Bispecific With Anti-TNF Activity In a Single Nanobody® Molecule

NCT06812988
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Brivekimig, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
12 Years to 35 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
5
States / cities
Atlanta, Georgia • Columbus, Georgia • Farmington Hills, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Sep 8, 2026, 9:14 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Regulation of Mucosal Healing in Inflammatory Bowel Disease

NCT04504136
View directory record Official record
Conditions
Inflammatory Bowel Diseases
Interventions
Serial Biopsy
Procedure
Lead sponsor
Terrence A Barrett
Other
Eligibility
18 Years to 90 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jun 7, 2025 · Synced Sep 8, 2026, 9:14 PM EDT
Completed No phase listed Observational

A Study of Comparing Rates of Dementia and Alzheimer's Disease in Participants Initiating Methotrexate Versus Those Initiating Anti-tumor Necrosis Factor (TNF)-Alpha Therapy

NCT04571697
View directory record Official record
Conditions
Dementia, Alzheimer Disease
Interventions
Methotrexate, Anti-TNF
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
34,647 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Titusville, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 26, 2025 · Synced Sep 8, 2026, 9:14 PM EDT
Completed No phase listed Observational

The Effect of Anti-HIV Treatment on Body Characteristics of HIV-Infected Children

NCT00006064
View directory record Official record
Conditions
HIV Infections, HIV Wasting Syndrome, Lipodystrophy
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Month to 12 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
2
States / cities
The Bronx, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 28, 2014 · Synced Sep 8, 2026, 9:14 PM EDT
Terminated Phase 4 Interventional Results available

Mechanistic Studies of B- and T-Cell Function in RA Patients Treated With TNF Antagonists, Tocilizumab, or Abatacept

NCT02353780
View directory record Official record
Conditions
Rheumatoid Arthritis (RA)
Interventions
TNF Antagonist (enbrel, humire, remicade, cimzia, symponi), Abatacept, Tocilizumab
Drug
Lead sponsor
Dr. Larry W. Moreland
Other
Eligibility
18 Years to 64 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 30, 2020 · Synced Sep 8, 2026, 9:14 PM EDT
Completed Phase 4 Interventional Results available

A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis

NCT03915964
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Baricitinib, TNF Inhibitor
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
2,659 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
81
States / cities
Flagstaff, Arizona • Gilbert, Arizona • Glendale, Arizona + 69 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Sep 8, 2026, 9:14 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Identifying Young Inflammatory Bowel Disease Patients at Risk for Herpes Zoster

NCT03553472
View directory record Official record
Conditions
Herpes Zoster, Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis
Interventions
Not listed
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
35 Years to 49 Years
Enrollment
97 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 18, 2019 · Synced Sep 8, 2026, 9:14 PM EDT
Completed Phase 2 Interventional Results available

A Study To Monitor Long-Term Treatment With PF-00547659

NCT01298492
View directory record Official record
Conditions
Crohn's Disease
Interventions
PF-00547659
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 75 Years
Enrollment
268 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
47
States / cities
La Jolla, California • Orange, California • Lafayette, Colorado + 21 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2021 · Synced Sep 8, 2026, 9:14 PM EDT
Terminated Phase 2 Interventional Results available

Evaluation of Efficacy and Safety of Brazikumab (MEDI2070) in Participants With Active, Moderate to Severe Crohn's Disease

NCT02574637
View directory record Official record
Conditions
Crohn's Disease
Interventions
Brazikumab IV Infusion, Brazikumab SC Injection, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 80 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
52
States / cities
Phoenix, Arizona • Lone Tree, Colorado • Clearwater, Florida + 25 more
Source: ClinicalTrials.gov public record
Updated May 25, 2021 · Synced Sep 8, 2026, 9:14 PM EDT